Leili Gao

Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study

Xiaoxu Huo, Leili Gao, Lixin Guo et al. · The Lancet Diabetes & Endocrinology · 2015 · 235 citations

Diabetes Epidemiology, Cardiovascular Epidemiology, Cardiovascular Disease +8

Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial

Leili Gao, Byung‐Wan Lee, Manoj Chawla et al. · Nature Medicine · 2023 · 88 citations · Full text

Metabolic Syndrome, Diabetes Management, Surpass-ap-combo Trial +9

The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999–2004

Li Li, Qi Huang, Yang Linjian et al. · Nutrients · 2022 · 73 citations · Full text

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial

Linong Ji, Leili Gao, Hongwei� Jiang et al. · EClinicalMedicine · 2022 · 68 citations · Full text

Serum Albumin, but not Bilirubin, is Associated with Diabetic Chronic Vascular Complications in a Chinese Type 2 Diabetic Population

Yu Zhu, Xiaoling Cai, Yan Liu et al. · Scientific Reports · 2019 · 31 citations · Full text